 |
Indication & Dosage |
| |
| |
| Oral |
| MUSCULOSKELETAL AND JOINT DISORDERS SUCH AS ANKYLOSING SPONDYLITIS, OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS |
| Adult:
0 mg as a single daily dose given for 7 days in acute musculoskeletal disorders and up to 14 days in severe cases. Max: 40mg/day (short term use). |
| |
| Oral |
| SHORT-TERM MANAGEMENT OF SOFT TISSUE INJURY |
| Adult:
0 mg as a single daily dose given for 7 days in acute musculoskeletal disorders and up to 14 days in severe cases. Max: 40mg/day (short term use). |
| |
| Parenteral |
| SHORT-TERM MANAGEMENT OF SOFT TISSUE INJURY |
| Adult:
Initially, 20 mg IM/IV as a single dose given for 1-2 days. |
| |
| Parenteral |
| MUSCULOSKELETAL AND JOINT DISORDERS SUCH AS ANKYLOSING SPONDYLITIS, OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS |
| Adult:
Initially, 20 mg IM/IV as a single dose given for 1-2 days. |
|
| |
|
| Administration |
Should be taken with food. (Take w/ or immediately after meals.) |
| |
|
| Precautions |
History of peptic ulceration, renal, cardiac or hepatic impairment, cerebovascular disease, fluid retention, inflammatory bowel disease, pregnancy, elderly. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
GI upsets including epigastric pain and gastritis, nausea, hypersensitivity reactions, headache, dizziness, sleep disturbances. |
| |
|
| Adverse Drug Reactions |
CV thrombotic events, blood dyscrasias, nephrotoxicity, hepatotoxicity, toxic epidermal necrolysis, Stevens-Johnson syndrome. |
| |
|
| Interactions |
Risk of nephrotoxicity may be increased with ACE inhibitors, ciclosporin, tacrolimus or diuretics. Increased risk of hyperkaelemia with ACE inhibitors, potassium sparing diuretics. |
| |
|
|
|
